AG˹ٷ

STOCK TITAN

Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2026

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Kewaunee Scientific (NASDAQ: KEQU) reported strong Q1 FY2026 results with sales reaching $71.1 million, up 46.9% year-over-year. The company achieved net earnings of $3.1 million ($1.04 per diluted share), compared to $2.2 million ($0.74 per share) in the prior year.

The company's order backlog stood at $205.0 million as of July 31, 2025, up from $159.4 million year-over-year. Domestic segment sales increased 53.0% to $54.4 million, while International segment sales grew 30.2% to $16.8 million. The growth was partially driven by the incorporation of Nu Aire's results, following its acquisition in November 2024.

Despite anticipating uneven quarterly performance for the remainder of FY2026, management expects to deliver improved unadjusted EBITDA compared to FY2025, while continuing strategic investments in corporate infrastructure.

[ "Sales increased significantly by 46.9% to $71.1 million year-over-year", "Net earnings grew 41% to $3.1 million compared to prior year", "Strong order backlog of $205.0 million, up 28.6% from prior year", "Domestic segment sales surged 53.0% to $54.4 million", "International segment sales increased 30.2% to $16.8 million", "Debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1" ]

Kewaunee Scientific (NASDAQ: KEQU) ha pubblicato solidi risultati per il primo trimestre dell’esercizio 2026: i ricavi sono saliti del 46,9% su base annua, raggiungendo $71,1 milioni. L’azienda ha realizzato un utile netto di $3,1 milioni (pari a $1,04 per azione diluita), rispetto ai $2,2 milioni ($0,74 per azione) dell’anno precedente.

Il portafoglio ordini al 31 luglio 2025 era di $205,0 milioni, in aumento rispetto ai $159,4 milioni dell’anno precedente. Le vendite sul mercato interno sono cresciute del 53,0%, arrivando a $54,4 milioni, mentre quelle internazionali sono aumentate del 30,2% a $16,8 milioni. Una parte della crescita riflette l’inclusione dei risultati di Nu Aire, acquisita nel novembre 2024.

La direzione prevede una performance trimestrale irregolare per il resto dell’esercizio 2026, ma si attende un miglioramento dell’EBITDA non rettificato rispetto al 2025, continuando al contempo gli investimenti strategici nelle infrastrutture aziendali.

  • Vendite +46,9% a $71,1 milioni anno su anno
  • Utile netto in crescita del 41% a $3,1 milioni rispetto all’anno precedente
  • Portafoglio ordini solido: $205,0 milioni, +28,6% su base annua
  • Vendite domestiche +53,0% a $54,4 milioni
  • Vendite internazionali +30,2% a $16,8 milioni
  • Rapporto debito/patrimonio migliorato a 0,94:1 rispetto a 0,99:1

Kewaunee Scientific (NASDAQ: KEQU) presentó sólidos resultados en el primer trimestre del ejercicio 2026: las ventas aumentaron un 46,9% interanual, alcanzando $71,1 millones. La compañía obtuvo beneficio neto de $3,1 millones (equivalente a $1,04 por acción diluida), frente a $2,2 millones ($0,74 por acción) del año anterior.

El pedido pendiente al 31 de julio de 2025 era de $205,0 millones, superior a los $159,4 millones del año previo. Las ventas en el segmento doméstico subieron un 53,0% hasta $54,4 millones, y las del segmento internacional crecieron un 30,2% hasta $16,8 millones. Parte del crecimiento se debe a la incorporación de los resultados de Nu Aire, adquirida en noviembre de 2024.

La dirección espera un desempeño trimestral desigual durante el resto del ejercicio 2026, pero prevé una mejora del EBITDA no ajustado respecto a 2025, manteniendo inversiones estratégicas en la infraestructura corporativa.

  • Ventas +46,9% a $71,1 millones interanuales
  • Beneficio neto +41% a $3,1 millones respecto al año anterior
  • Sólida cartera de pedidos: $205,0 millones, +28,6% interanual
  • Ventas domésticas +53,0% a $54,4 millones
  • Ventas internacionales +30,2% a $16,8 millones
  • Ratio deuda/capital mejoró a 0,94:1 desde 0,99:1

Kewaunee Scientific (NASDAQ: KEQU)� 2026 회계연도 1분기에서 견조� 실적� 발표했습니다. 매출은 전년 동기 대� 46.9% 증가� $71.1백만� 기록했고, 순이익은 $3.1백만($1.04 희석 주당순이�)으로 전년� $2.2백만($0.74 주당)� 비해 개선되었습니�.

2025� 7� 31� 기준 수주 잔고� $205.0백만으로 전년� $159.4백만에서 늘었습니�. 국내 부� 매출은 53.0% 증가� $54.4백만, 국제 부� 매출은 30.2% 증가� $16.8백만� 기록했습니다. 이러� 성장은 2024� 11� 인수� Nu Aire� 실적 편입� 일부 기인합니�.

경영진은 2026 회계연도 나머지 기간 동안 분기� 실적� 불규칙할 것으� 예상하지�, 2025년보� 개선� 비조� EBITDA� 달성� 것으� 기대하며 기업 인프라에 대� 전략� 투자� 계속� 예정입니�.

  • 매출 전년 대� 46.9% 증가, $71.1백만
  • 순이� 41% 증가, $3.1백만
  • 수주 잔고 견조: $205.0백만, 전년 대� +28.6%
  • 국내 매출 53.0% 증가, $54.4백만
  • 국제 매출 30.2% 증가, $16.8백만
  • 부채비�(부�/자본) 0.99에서 0.94� 개선

Kewaunee Scientific (NASDAQ: KEQU) a publié de solides résultats pour le 1er trimestre de l’exercice 2026 : les ventes ont augmenté de 46,9% en glissement annuel pour atteindre 71,1 M$. La société a réalisé un bénéfice net de 3,1 M$ (soit 1,04 $ par action diluée), contre 2,2 M$ (0,74 $ par action) l’an précédent.

Le carnet de commandes au 31 juillet 2025 s’élevait à 205,0 M$, en hausse par rapport à 159,4 M$ un an plus tôt. Les ventes nationales ont progressé de 53,0% à 54,4 M$, tandis que les ventes internationales ont augmenté de 30,2% à 16,8 M$. Cette croissance reflète en partie l’intégration des résultats de Nu Aire, acquis en novembre 2024.

La direction anticipe des performances trimestrielles irrégulières pour le reste de l’exercice 2026, mais s’attend à une amélioration de l’EBITDA non retraité par rapport à 2025, tout en poursuivant des investissements stratégiques dans l’infrastructure du groupe.

  • Ventes +46,9% à 71,1 M$ en glissement annuel
  • Bénéfice net +41% à 3,1 M$ par rapport à l’an précédent
  • Carnet de commandes solide : 205,0 M$, +28,6% sur un an
  • Ventes nationales +53,0% à 54,4 M$
  • Ventes internationales +30,2% à 16,8 M$
  • Ratio dette/fonds propres amélioré à 0,94:1 contre 0,99:1

Kewaunee Scientific (NASDAQ: KEQU) meldete starke Ergebnisse für das erste Quartal des Geschäftsjahres 2026: Der Umsatz stieg um 46,9% gegenüber dem Vorjahr auf $71,1 Mio.. Das Unternehmen erzielte einen Reingewinn von $3,1 Mio. (entsprechend $1,04 je verwässerter Aktie) gegenüber $2,2 Mio. ($0,74 je Aktie) im Vorjahr.

Der Auftragsbestand belief sich zum 31. Juli 2025 auf $205,0 Mio., nach $159,4 Mio. im Vorjahr. Die inländischen Umsätze wuchsen um 53,0% auf $54,4 Mio., die internationalen Umsätze um 30,2% auf $16,8 Mio.. Ein Teil des Wachstums ist auf die Einbeziehung der Ergebnisse von Nu Aire zurückzuführen, das im November 2024 übernommen wurde.

Das Management erwartet für den weiteren Verlauf des Geschäftsjahres 2026 ungleichmäßig verlaufende Quartale, rechnet aber mit einer Verbesserung des unbereinigten EBITDA gegenüber 2025 und setzt gleichzeitig strategische Investitionen in die Unternehmensinfrastruktur fort.

  • Umsatz +46,9% auf $71,1 Mio. gegenüber dem Vorjahr
  • Reingewinn +41% auf $3,1 Mio. gegenüber dem Vorjahr
  • Starker Auftragsbestand: $205,0 Mio., +28,6% gegenüber dem Vorjahr
  • Inländische Umsätze +53,0% auf $54,4 Mio.
  • Internationale Umsätze +30,2% auf $16,8 Mio.
  • Verschuldungsgrad verbesserte sich von 0,99:1 auf 0,94:1
Positive
  • None.
Negative
  • Project delivery timelines experiencing volatility, expecting uneven performance in upcoming quarters
  • Increased corporate costs due to strategic investments and compliance requirements
  • Corporate segment pre-tax net loss increased to $3.1 million from $2.0 million year-over-year
  • Challenging market conditions due to uncertain government policy and geopolitical issues

Insights

Kewaunee reports robust Q1 growth with 46.9% higher sales and 61.3% increased pre-tax earnings, though warning of uneven future performance.

Kewaunee Scientific's Q1 FY2026 results demonstrate impressive growth across key metrics. Sales jumped 46.9% to $71.1 million compared to the prior year, while pre-tax earnings increased 61.3% to $3.92 million. This translated to diluted EPS of $1.04, up from $0.74 year-over-year.

The company's order backlog stands at $205 million, significantly higher than the $159.4 million from the year-ago period, though slightly down from $214.6 million at fiscal year-end. This robust backlog provides approximately 9 months of sales visibility at current execution rates.

Segment performance reveals the domestic market as the primary growth driver, with sales increasing 53% to $54.4 million and segment earnings rising 64.5% to $4.7 million. The acquisition of Nu Aire (completed November 2024) has clearly bolstered these results. Meanwhile, international operations showed solid improvement with sales up 30.2% to $16.8 million, as previous customer site delays have begun to resolve.

Despite these strong results, management has cautioned investors about potential quarterly volatility for the remainder of FY2026, particularly starting in Q2. The warning stems from project delivery timeline fluctuations amid challenging market conditions, including "uncertain government policy, evolving tariff structures and broader geopolitical upheaval."

The balance sheet shows $20.4 million in cash, up from $17.2 million at fiscal year-end, while total debt decreased slightly. The debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1 at fiscal year-end, with the sale-leaseback adjusted ratio at 0.54-to-1.

Management's strategic investments in corporate infrastructure are creating near-term pressure on the bottom line (corporate segment loss increased to $3.1 million from $2 million), but these expenditures in people, processes, and technology appear aimed at supporting sustainable long-term growth. Despite expectations of uneven quarterly performance, management remains confident in delivering improved EBITDA for the full fiscal year compared to FY2025.

STATESVILLE, N.C., Sept. 10, 2025 /PRNewswire/ -- PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first quarter ended July 31, 2025.

Fiscal Year 2026 First Quarter Results:

Sales during the first quarter of fiscal year 2026 were $71,104,000, an increase of 46.9% compared to sales of $48,393,000 from the prior year's first quarter. Pre-tax earnings for the quarter were $3,920,000 compared to $2,430,000 for the prior year quarter, an increase of 61.3%. Net earnings were $3,093,000 compared to net earnings of $2,193,000 for the prior year quarter. EBITDA1 for the quarter was $6,320,000 compared to $3,325,000 for the prior year quarter. Diluted earnings per share were $1.04 compared to diluted earnings per share of $0.74 in the prior year quarter.

The Company's order backlog was $205.0million on July 31, 2025, as compared to $159.4million on July 31, 2024, and $214.6million on April 30, 2025.

Domestic Segment- Domestic sales for the quarter were $54,352,000, an increase of 53.0% from sales of $35,523,000 in the prior year quarter. Domestic segment net earnings were $4,722,000 compared to $2,871,000 in the prior year quarter. Domestic segment EBITDA was $7,576,000 compared to $4,738,000 for the prior year quarter. The increase in Domestic sales and earnings was driven by the incorporation of Nu Aire's results, steady manufacturing volumes, improved productivity, and cost management actions.

International Segment- International sales for the quarter were $16,752,000, an increase of 30.2% from sales of $12,870,000 in the prior year quarter. International segment net earnings were $643,000 compared to $463,000 in the prior year quarter. International segment EBITDA was $1,055,000 compared to $696,000 for the prior year quarter. The impact of customer site delays experienced during most of the prior fiscal year began decreasing during the fourth quarter of fiscal year 2025, resulting in increased deliveries and billings for the first quarter of fiscal year 2026 compared to the comparable prior year period.

Corporate Segment� Corporate segment pre-tax net loss was $3,058,000 for the quarter, as compared to a pre-tax net loss of $1,992,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,311,000) compared to corporate segment EBITDA of ($2,109,000) for the prior year quarter. Corporate segment EBITDA remained relatively stable year over year, despite the inclusion of $730,000 of costs in the prior year period results directly related to the acquisition of Nu Aire, Inc., which closed on November 1, 2024. In the current year period, the Company incurred costs related to its strategic investment in its Corporate platform. These investments include increased compliance costs related to the anticipated triggering of Sarbanes-Oxley 404(b) requirements and strategic investments in people, processes, and technology to continue to build out the Company's Corporate platform in order to support future anticipated growth.

Total cash on hand on July 31, 2025, was $20,441,000, as compared to $17,164,000 on April 30, 2025. Working capital was $66,662,000, as compared to $56,012,000 at the end of the first quarter last year and $64,651,000 on April 30, 2025.

The Company had short-term debt of $4,294,000 as of July 31, 2025, as compared to $4,773,000 on April 30, 2025. Long-term debt was $60,269,000 on July 31, 2025, as compared to $60,730,000 on April 30, 2025. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $26,420,000 of the long-term debt on July 31, 2025, and $26,632,000 of the long-term debt on April 30, 2025. Long-term debt, net of the sale-leaseback transaction, was $33,849,000 on July 31, 2025, as compared to $34,098,000 on April 30, 2025. The Company's debt-to-equity ratio on July 31, 2025, was 0.94-to-1, as compared to 0.99-to-1 on April30, 2025. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on July 31, 2025, was 0.54-to-1, as compared to 0.57-to-1 on April 30, 2025.

"Our Domestic and International segments delivered solid financial performance in the first quarter despite challenging market conditions as a result of uncertain government policy, evolving tariff structures and broader geopolitical upheaval," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "While our overall backlog remains near historically high levels, we are experiencing volatility in project delivery timelines that we expect will cause uneven performance by quarter for the balance of fiscal year 2026, likely starting in the second quarter. This is a reality of both the uncertainty in the market, and the nature of construction-related manufacturing, where project timing often shifts, causing peaks and valleys in production schedules."

"Kewaunee is focused on growth, both organically and inorganically, and is committed to making strategic investments in the people, processes, and technology that will support and enable this growth in a sustainable manner. These important investments are accounted for in the Corporate segment and, while some of the costs are expected to be non-recurring in nature, many of them will not be. Though this will place pressure on earnings growth in the near term, we believe it will position Kewaunee for rapid and sustained growth in the future, allowing us to gain leverage on these investments over the long term."

"Despite our anticipation of uneven quarterly performance for the remainder of fiscal year 2026, and increasing strategic investment in the Corporate platform, we expect to deliver better unadjusted EBITDA in fiscal year 2026 than we did in fiscal year 2025. We are confident in the strategies we are employing and the long-term health of the business."

1EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.

EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation

(Unaudited)

($ in thousands)

Quarter Ended July 31, 2024


Domestic


International


Corporate


Consolidated

Net Earnings (Loss)


$ 2,871


$ 463


$ (1,141)


$ 2,193

Add/(Less):









Interest Expense


441


21


10


472

Interest Income



(174)


(173)


(347)

Income Taxes


764


279


(851)


192

Depreciation and Amortization


662


107


46


815

EBITDA


$ 4,738


$ 696


$ (2,109)


$ 3,325

Professional Fees2




730


730

Adjusted EBITDA


$ 4,738


$ 696


$ (1,379)


$ 4,055










Quarter Ended July 31, 2025


Domestic


International


Corporate


Consolidated

Net Earnings (Loss)


$ 4,722


$ 643


$ (2,272)


$ 3,093

Add/(Less):









Interest Expense


313


13


732


1,058

Interest Income



(131)


(10)


(141)

Income Taxes


1,113


434


(786)


761

Depreciation and Amortization


1,428


96


25


1,549

EBITDA


$ 7,576


$ 1,055


$ (2,311)


$ 6,320

Professional & Other Fees3




224


224

Adjusted EBITDA


$ 7,576


$ 1,055


$ (2,087)


$ 6,544











2 Professional and other fees incurred during the three months ended July 31, 2024 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024

3 Professional and other fees incurred during the three months ended July 31, 2025 related to the Company's integration of its newly acquired subsidiary, Nu Aire

Adjusted Consolidated Statement of Operations Reconciliation

(Unaudited)

($ in thousands, except per share amounts)


Three Months Ended July 31,


As Reported
2025


Professional
& Other Fees4


Adjusted
2025


Adjusted
2024

Net sales

$ 71,104


$ �


$ 71,104


$ 48,393

Cost of products sold

50,174



50,174


35,905

Gross profit

20,930



20,930


12,488

Operating expenses

16,120


224


15,896


9,183

Operating profit

4,810


224


5,034


3,305

Other income, net

168



168


327

Interest expense

(1,058)



(1,058)


(472)

Profit before income taxes

3,920


224


4,144


3,160

Income tax (benefit) expense

761


49


810


345

Net earnings

3,159


175


3,334


2,815

Less: Net earnings attributable to the non-controlling interest

66



66


45

Net earnings attributable to Kewaunee Scientific Corporation

$ 3,093


$ 175


$ 3,268


$ 2,770









Net earnings per share attributable to Kewaunee Scientific
Corporation stockholders








Basic

$ 1.08


$ 0.06


$ 1.15


$ 0.97

Diluted

$ 1.04


$ 0.06


$ 1.10


$ 0.93


4 Professional and other fees incurred during the three months ended July 31, 2025 related to the Company's integration of its newly acquired subsidiary, Nu Aire, including the estimated tax impact

About Non-GAAP Measures

The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the integration of the Company's newly acquired subsidiary, Nu Aire, Inc., and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's integration of its newly acquired subsidiary, Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to interest expense and interest income, income taxes, depreciation, amortization or the costs incurred related to the integration of Nu Aire, Inc., which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.

About Kewaunee Scientific

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets.

Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China.

Learn more at the companies' websites, located at and .

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2025, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at and on the SEC website at . These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Kewaunee Scientific Corporation

Condensed Consolidated Statements of Operations

(Unaudited)

($ and shares in thousands, except per share amounts)



Three Months Ended

July 31,


2025


2024

Net sales

$ 71,104


$ 48,393

Cost of products sold

50,174


35,905

Gross profit

20,930


12,488

Operating expenses

16,120


9,913

Operating profit

4,810


2,575

Other income, net

168


327

Interest expense

(1,058)


(472)

Profit before income taxes

3,920


2,430

Income tax expense

761


192

Net earnings

3,159


2,238

Less: Net earnings attributable to the non-controlling interest

66


45

Net earnings attributable to Kewaunee Scientific Corporation

$ 3,093


$ 2,193





Net earnings per share attributable to Kewaunee Scientific Corporation
stockholders




Basic

$ 1.08


$ 0.77

Diluted

$ 1.04


$ 0.74

Weighted average number of common shares outstanding




Basic

2,851


2,849

Diluted

2,963


2,967

Kewaunee Scientific Corporation

Condensed Consolidated Balance Sheets

($ in thousands)



July 31, 2025


April 30, 2025


(Unaudited)



Assets




Cash and cash equivalents

$ 19,489


$ 14,942

Restricted cash

952


2,222

Receivables, less allowances

56,897


62,384

Inventories

34,923


32,849

Prepaid expenses and other current assets

4,887


5,966

Total Current Assets

117,148


118,363

Net property, plant and equipment

22,781


23,174

Right of use assets

12,022


12,965

Deferred income taxes

4,211


3,994

Net intangible assets

17,447


17,831

Goodwill

12,487


12,487

Other assets

7,390


5,840

Total Assets

$ 193,486


$ 194,654





Liabilities and Stockholders' Equity




Short-term borrowings

$ 495


$ 986

Current portion of lease obligations

3,220


3,371

Current portion of financing liability

807


788

Current portion of term loan

2,903


2,903

Accounts payable

26,327


27,033

Other current liabilities

16,734


18,631

Total Current Liabilities

50,486


53,712

Long-term portion of lease obligations

8,156


8,946

Long-term portion of financing liability

26,420


26,632

Long-term portion of seller note

24,021


23,537

Long-term portion of term loan

9,686


10,412

Other non-current liabilities

5,848


5,170

Total Liabilities

124,617


128,409

Kewaunee Scientific Corporation Equity

67,078


64,457

Non-controlling interest

1,791


1,788

Total Stockholders' Equity

68,869


66,245

Total Liabilities and Stockholders' Equity

$ 193,486


$ 194,654

Contact:

Donald T. Gardner III


704/871-3274

Cision View original content to download multimedia:

SOURCE Kewaunee Scientific Corporation

FAQ

What were Kewaunee Scientific's (KEQU) Q1 2026 earnings results?

Kewaunee reported Q1 FY2026 net earnings of $3.1 million ($1.04 per diluted share), with sales of $71.1 million, representing a 46.9% increase year-over-year.

How much is Kewaunee Scientific's (KEQU) current order backlog?

As of July 31, 2025, Kewaunee's order backlog stood at $205.0 million, compared to $159.4 million in the prior year, representing a 28.6% increase.

What was KEQU's domestic segment performance in Q1 2026?

Kewaunee's domestic segment sales reached $54.4 million, a 53.0% increase from $35.5 million in the prior year, with segment net earnings of $4.7 million.

How has the Nu Aire acquisition impacted Kewaunee Scientific's performance?

The Nu Aire acquisition has contributed to Kewaunee's growth, particularly in the Domestic segment, though the company incurred $224,000 in integration-related costs during Q1 FY2026.

What is Kewaunee Scientific's outlook for fiscal year 2026?

Despite expecting uneven quarterly performance, management anticipates delivering better unadjusted EBITDA in FY2026 compared to FY2025, while continuing strategic investments in corporate infrastructure.
Kewaunee Scienti

NASDAQ:KEQU

KEQU Rankings

KEQU Latest News

KEQU Latest SEC Filings

KEQU Stock Data

161.50M
2.21M
23.58%
38.86%
1.36%
Furnishings, Fixtures & Appliances
Laboratory Apparatus & Furniture
United States
STATESVILLE